CompletedPhase 4

VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

United States73 participantsStarted 2005-03-29

Plain-language summary

Eligible subjects will be randomized to receive VALTREX® tablet 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days between treatment periods.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * In overall general good health. * HSV-2 (Herpes Simplex Virus-2) seropositive at screening. Exclusion criteria: * have active lesions consistent with genital herpes. * previous history of symptomatic genital herpes. * history of recurrent, undiagnosed symptoms consistent with genital herpes.

What they're measuring

Mean Percent Days of Subclinical Shedding as Determined by Type-specific Polymerase Chain Reaction (PCR) Assay for HSV-2

Timeframe: Up to Day 60 of each treatment period (up to 160 days)

Trial details

NCT IDNCT00116844

SponsorGlaxoSmithKline

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2006-01-10

Results submitted2017-03-16

View on ClinicalTrials.gov More Infections, Herpesviridae trials